...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study
【24h】

The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study

机译：乳腺癌患者乳腺癌患者在佐剂化疗期间乳腺癌患者的疗效：随机对照研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective . The randomized controlled clinical trial aims to investigate the clinical efficacy of moxibustion for breast cancer patients with chemotherapy-induced myelosuppression (CIM) during adjuvant chemotherapy. Methods . Surgically resected breast cancer patients were randomly divided into the moxibustion group (MOX; n ?=?48) and control group (CON; n ?=?44). Routine adjuvant chemotherapy (every 21 days, 4–8 cycles) and supportive recombinant human granulocyte colony-stimulating factor were given to both groups, while MOX received an additional moxibustion treatment (once daily after each cycle of chemotherapy). Primary endpoints included the grade of myelosuppression in terms of white blood cell (WBC) and absolute neutrophil count (ANC) and the incidence of myelosuppression-related serious adverse events (SAEs). Other measures included treatment compliance, adverse events (AEs), and survival. Results . WBC counts were generally higher in MOX and were dramatically higher than those in CON at the 7 th course of chemotherapy ( ), while grade 1 ANC reduction was dramatically lower than that in CON at the 7 th course of chemotherapy ( ). These effects were particularly significant in patients receiving anthracycline-taxane combination regimens. Moreover, MOX had fewer febrile neutropenia than CON ( ). MOX demonstrated a lower incidence of grade 3–4 myelosuppression ( ). AEs including grade 2–3 severe nausea, various kinds of pains, and vertigo occurred less frequently in MOX ( ). No difference in survival was observed between the two groups ( ). Conclusion . Moxibustion is effective for treating CIM in breast cancer patients during adjuvant chemotherapy, especially for patients receiving high-dose, long-term, and combined chemotherapy regimens. Moxibustion can reduce the incidence of myelosuppression-related SAE and improve the compliance and safety of chemotherapy in breast cancer.
机译：客观的 。随机对照临床试验旨在探讨乳腺癌患者在佐剂化疗期间患有化疗诱导的髓质抑制（CIM）的乳腺癌患者的临床疗效。方法 。手术切除的乳腺癌患者随机分为艾灸组（MOX; N？= 48）和对照组（CON; N？=？44）。常规佐剂化疗（每21天，4-8个循环）和支持性重组人粒细胞菌落刺激因子对两个组发出，而MOX接受了另外的艾灸治疗（每次化疗后每天一次）。主要终点包括白细胞（WBC）和绝对中性粒细胞计数（ANC）和骨髓抑制相关严重不良事件（SAES）的发病率方面的髓抑制等级。其他措施包括治疗顺应性，不良事件（AES）和生存。结果 。 MOX的WBC计数通常较高，并且在第7级化疗（）的疗程中显着高于CON，而1级ANC减少在第7阶段的化疗（）中的CON中的变化显着低。这些效果在接受蒽环类紫杉烷组合方案的患者中特别显着。此外，MOX比CON（）较少。 MOX显示出3-4级骨髓抑制（）的发病率较低。 AES在包括2-3级严重恶心，各种痛苦和眩晕的AES在MOX（）中常常较不常见。两组（）之间观察到存活差异。结论 。艾灸在佐剂化疗期间治疗乳腺癌患者的CIM是有效的，特别是对于接受高剂量，长期和组合化疗方案的患者。艾灸可以减少髓抑制相关的SAE的发病率，并改善乳腺癌化疗的合规性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号